Single-Nucleus Transcriptomics Uncovers Xaf1-Driven PANoptosis as a Therapeutic Target in Aminoglycoside-Induced Hearing Loss

Abstract

Aminoglycoside antibiotics are essential in managing many life-threatening diseases. However, their derivatives, such as neomycin, are associated with severe side effects such as persistent sensorineural hearing loss. Therefore, it is essential to elucidate the molecular and biochemical mechanisms of aminoglycoside-induced ototoxicity and identify targets for alleviating ototoxic injury. Here, we provide a detailed cochlear cell atlas of neomycin-induced acute and chronic ototoxicity-related changes through single-nucleus RNA sequencing profiling. Utilising this cochlear cell atlas, we used the Augur and scDist algorithms to evaluate cell-type-specific susceptibility to neomycin injury. We observed aberrant expression of X-linked inhibitor of apoptosis (Xiap)–associated factor 1 (Xaf1) in neomycin-exposed cochleae using the cochlear cell atlas, and we identified a novel role for Xaf1 in facilitating PANoptosis through overexpression and knockdown assays in vitro. Finally, we assessed the protective role of Xaf1 against neomycin-induced ototoxicity by Xaf1 knockdown in cochlear hair cells using adeno-associated virus-based gene delivery. Mechanistically, Xaf1 orchestrates PANoptosis activation through direct interaction with and transcriptional regulation of ZBP1, establishing its hierarchical position upstream in the signalling cascade. This study presents detailed cochlear cellular maps of neomycin-induced ototoxicity and serves as a valuable resource for identifying transcriptome-wide disease-driving perturbations at the single-cell level. More importantly, we identified Xaf1 as a critical target for modulating the PANoptosis pathway, offering a promising treatment strategy for aminoglycoside-induced ototoxicity.

Keywords

hair cell / neomycin / PANoptosis / snRNA-seq / Xaf1

References

[1] S. Chadha, K. Kamenov, and A. Cieza, “The World Report on Hearing, 2021,” Bulletin of the World Health Organization 99, no. 4 (2021): 242–242a.

[2] M. C. Liberman and S. G. Kujawa, “Cochlear Synaptopathy in Acquired Sensorineural Hearing Loss: Manifestations and Mechanisms,” Hearing Research 349 (2017): 138–147.

[3] L. Li, T. Chao, J. Brant, B. O'Malley,, A. Tsourkas, and D. Li, “Advances in Nano-Based Inner Ear Delivery Systems for the Treatment of Sensorineural Hearing Loss,” Advanced Drug Delivery Reviews 108 (2017): 2–12.

[4] J. Wang and J. L. Puel, “Toward Cochlear Therapies,” Physiological Reviews 98, no. 4 (2018): 2477–2522.

[5] J. Kim, S. Hemachandran, A. G. Cheng, and A. J. Ricci, “Identifying Targets to Prevent Aminoglycoside Ototoxicity,” Molecular and Cellular Neurosciences 120 (2022): 103722.

[6] V. Arora, D. Strunk, S. H. Furqan, et al., “Optimizing Antibiotic Use for Early Onset Sepsis: A Tertiary NICU Experience,” Journal of Neonatal-Perinatal Medicine 12, no. 3 (2019): 301–312.

[7] J. H. McDermott, A. Mahaveer, R. A. James, et al., “Rapid Point-Of-Care Genotyping to Avoid Aminoglycoside-Induced Ototoxicity in Neonatal Intensive Care,” JAMA Pediatrics 176, no. 5 (2022): 486–492.

[8] B. L. Meatherall, D. Gregson, T. Ross, J. D. Pitout, and K. B. Laupland, “Incidence, Risk Factors, and Outcomes of Klebsiella Pneumoniae Bacteremia,” American Journal of Medicine 122, no. 9 (2009): 866–873.

[9] K. A. Wargo and J. D. Edwards, “Aminoglycoside-Induced Nephrotoxicity,” Journal of Pharmacy Practice 27, no. 6 (2014): 573–577.

[10] L. K. Dillard, R. X. Martinez, L. L. Perez, A. M. Fullerton, S. Chadha, and C. M. McMahon, “Prevalence of Aminoglycoside-Induced Hearing Loss in Drug-Resistant Tuberculosis Patients: A Systematic Review,” Journal of Infection 83, no. 1 (2021): 27–36.

[11] D. Sharma, B. Kumar, M. Lata, et al., “Comparative Proteomic Analysis of Aminoglycosides Resistant and Susceptible Mycobacterium tuberculosis Clinical Isolates for Exploring Potential Drug Targets,” PLoS One 10, no. 10 (2015): e0139414.

[12] M. Strupp and V. Arbusow, “Acute Vestibulopathy,” Current Opinion in Neurology 14, no. 1 (2001): 11–20.

[13] L. P. Rybak and T. Kelly, “Ototoxicity: Bioprotective Mechanisms,” Current Opinion in Otolaryngology & Head and Neck Surgery 11, no. 5 (2003): 328–333.

[14] A. Forge and J. Schacht, “Aminoglycoside Antibiotics,” Audiology & Neuro-Otology 5, no. 1 (2000): 3–22.

[15] P. S. Roland, “New Developments in Our Understanding of Ototoxicity,” Ear, Nose, & Throat Journal 83, no. 9 Suppl 4 (2004): 15–16.

[16] G. Sahoo, D. Samal, P. Khandayataray, and M. K. Murthy, “A Review on Caspases: Key Regulators of Biological Activities and Apoptosis,” Molecular Neurobiology 60, no. 10 (2023): 5805–5837.

[17] L. Kolla, M. C. Kelly, Z. F. Mann, et al., “Characterization of the Development of the Mouse Cochlear Epithelium at the Single Cell Level,” Nature Communications 11, no. 1 (2020): 2389.

[18] U. Müller and P. G. Barr-Gillespie, “New Treatment Options for Hearing Loss,” Nature Reviews. Drug Discovery 14, no. 5 (2015): 346–365.

[19] D. R. McPherson, “Sensory Hair Cells: An Introduction to Structure and Physiology,” Integrative and Comparative Biology 58, no. 2 (2018): 282–300.

[20] E. L. Monzack and L. L. Cunningham, “Lead Roles for Supporting Actors: Critical Functions of Inner Ear Supporting Cells,” Hearing Research 303 (2013): 20–29.

[21] P. Wangemann, “K+ Cycling and the Endocochlear Potential,” Hearing Research 165, no. 1–2 (2002): 1–9.

[22] T. Nicolson, “Navigating Hereditary Hearing Loss: Pathology of the Inner Ear,” Frontiers in Cellular Neuroscience 15 (2021): 660812.

[23] B. Chen, C. Cheng, Y. Wu, et al., “PGC-1α-Mediated Imbalance of Mitochondria-Lipid Droplet Homeostasis in Neomycin-Induced Ototoxicity and Nephrotoxicity,” Acta Pharmaceutica Sinica B 14, no. 10 (2024): 4413–4430.

[24] P. Jean, F. Wong Jun Tai, A. Singh-Estivalet, et al., “Single-Cell Transcriptomic Profiling of the Mouse Cochlea: An Atlas for Targeted Therapies,” Proceedings of the National Academy of Sciences of the United States of America 120, no. 26 (2023): e2221744120.

[25] X. Fu, P. Wan, P. Li, et al., “Mechanism and Prevention of Ototoxicity Induced by Aminoglycosides,” Frontiers in Cellular Neuroscience 15 (2021): 692762.

[26] R. K. S. Malireddi, S. Kesavardhana, and T. D. Kanneganti, “ZBP1 and TAK1: Master Regulators of NLRP3 Inflammasome/Pyroptosis, Apoptosis, and Necroptosis (PAN-Optosis),” Frontiers in Cellular and Infection Microbiology 9 (2019): 406.

[27] D. W. Nicholson, A. Ali, N. A. Thornberry, et al., “Identification and Inhibition of the ICE/CED-3 Protease Necessary for Mammalian Apoptosis,” Nature 376, no. 6535 (1995): 37–43.

[28] M. Tewari, L. T. Quan, K. O'Rourke, et al., “Yama/CPP32 Beta, a Mammalian Homolog of CED-3, Is a CrmA-Inhibitable Protease That Cleaves the Death Substrate Poly(ADP-Ribose) Polymerase,” Cell 81, no. 5 (1995): 801–809.

[29] Y. Wang and T. D. Kanneganti, “From Pyroptosis, Apoptosis and Necroptosis to PANoptosis: A Mechanistic Compendium of Programmed Cell Death Pathways,” Computational and Structural Biotechnology Journal 19 (2021): 4641–4657.

[30] J. Shi, Y. Zhao, K. Wang, et al., “Cleavage of GSDMD by Inflammatory Caspases Determines Pyroptotic Cell Death,” Nature 526, no. 7575 (2015): 660–665.

[31] N. Kayagaki, I. B. Stowe, B. L. Lee, et al., “Caspase-11 Cleaves Gasdermin D for Non-Canonical Inflammasome Signalling,” Nature 526, no. 7575 (2015): 666–671.

[32] H. Wang, L. Sun, L. Su, et al., “Mixed Lineage Kinase Domain-Like Protein MLKL Causes Necrotic Membrane Disruption Upon Phosphorylation by RIP3,” Molecular Cell 54, no. 1 (2014): 133–146.

[33] Z. Cai, S. Jitkaew, J. Zhao, et al., “Plasma Membrane Translocation of Trimerized MLKL Protein Is Required for TNF-Induced Necroptosis,” Nature Cell Biology 16, no. 1 (2014): 55–65.

[34] N. Holler, R. Zaru, O. Micheau, et al., “Fas Triggers an Alternative, Caspase-8-Independent Cell Death Pathway Using the Kinase RIP as Effector Molecule,” Nature Immunology 1, no. 6 (2000): 489–495.

[35] P. Liston, W. G. Fong, N. L. Kelly, et al., “Identification of XAF1 as an Antagonist of XIAP Anti-Caspase Activity,” Nature Cell Biology 3, no. 2 (2001): 128–133.

[36] W. Dai, P. Zheng, J. Wu, et al., “Integrated Analysis of Single-Cell RNA-Seq and Chipset Data Unravels PANoptosis-Related Genes in Sepsis,” Frontiers in Immunology 14 (2023): 1247131.

[37] M. G. Lee, J. S. Huh, S. K. Chung, et al., “Promoter CpG Hypermethylation and Downregulation of XAF1 Expression in Human Urogenital Malignancies: Implication for Attenuated p53 Response to Apoptotic Stresses,” Oncogene 25, no. 42 (2006): 5807–5822.

[38] S. K. Chung, M. G. Lee, B. K. Ryu, et al., “Frequent Alteration of XAF1 in Human Colorectal Cancers: Implication for Tumor Cell Resistance to Apoptotic Stresses,” Gastroenterology 132, no. 7 (2007): 2459–2477.

[39] S. C. Sun, “The Non-Canonical NF-κB Pathway in Immunity and Inflammation,” Nature Reviews. Immunology 17, no. 9 (2017): 545–558.

[40] S. Lee, R. Karki, Y. Wang, L. N. Nguyen, R. C. Kalathur, and T. D. Kanneganti, “AIM2 Forms a Complex With Pyrin and ZBP1 to Drive PANoptosis and Host Defence,” Nature 597, no. 7876 (2021): 415–419.

[41] X. Ma, J. Guo, M. Tian, et al., “Advance and Application of Single-Cell Transcriptomics in Auditory Research,” Neuroscience Bulletin 40, no. 7 (2024): 963–980.

[42] M. Wu, M. Xia, W. Li, and H. Li, “Single-Cell Sequencing Applications in the Inner Ear,” Frontiers in Cell and Development Biology 9 (2021): 637779.

[43] T. R. Sanders and M. W. Kelley, “Specification of Neuronal Subtypes in the Spiral Ganglion Begins Prior to Birth in the Mouse,” Proceedings of the National Academy of Sciences of the United States of America 119, no. 48 (2022): e2203935119.

[44] J. I. Matsui, J. M. Ogilvie, and M. E. Warchol, “Inhibition of Caspases Prevents Ototoxic and Ongoing Hair Cell Death,” Journal of Neuroscience : The Official Journal of the Society for Neuroscience 22, no. 4 (2002): 1218–1227.

[45] X. Jiang, L. Yin, N. Zhang, et al., “Bisphenol A Induced Male Germ Cell Apoptosis via IFNβ-XAF1-XIAP Pathway in Adult Mice,” Toxicology and Applied Pharmacology 355 (2018): 247–256.

[46] S. I. Jeong, J. W. Kim, K. P. Ko, et al., “XAF1 Forms a Positive Feedback Loop With IRF-1 to Drive Apoptotic Stress Response and Suppress Tumorigenesis,” Cell Death & Disease 9, no. 8 (2018): 806.

[47] N. Pandian and T. D. Kanneganti, “PANoptosis: A Unique Innate Immune Inflammatory Cell Death Modality,” Journal of Immunology (Baltimore, Md : 1950) 209, no. 9 (2022): 1625–1633.

[48] Q. Guo, Y. Jin, X. Chen, et al., “NF-κB in Biology and Targeted Therapy: New Insights and Translational Implications,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 53.

[49] Y. Zhang, S. Yu, X. Guo, L. Wang, L. Yu, and P. Wang, “Therapeutic Potential of Salidroside in Preserving Rat Cochlea Organ of Corti From Gentamicin-Induced Injury Through Modulation of NRF2 Signaling and GSK3β/NF-κB Pathway,” PLoS One 19, no. 3 (2024): e0298529.

[50] G. Zhang, H. Zheng, I. Pyykko, and J. Zou, “The TLR-4/NF-κB Signaling Pathway Activation in Cochlear Inflammation of Rats With Noise-Induced Hearing Loss,” Hearing Research 379 (2019): 59–68.

[51] X. Zhang, R. Cao, C. Li, et al., “Caffeine Ameliorates Age-Related Hearing Loss by Downregulating the Inflammatory Pathway in Mice,” Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 45, no. 3 (2024): 227–237.

[52] F. A. Wolf, P. Angerer, and F. J. Theis, “SCANPY: Large-Scale Single-Cell Gene Expression Data Analysis,” Genome Biology 19, no. 1 (2018): 15.

[53] R. Lopez, J. Regier, M. B. Cole, M. I. Jordan, and N. Yosef, “Deep Generative Modeling for Single-Cell Transcriptomics,” Nature Methods 15, no. 12 (2018): 1053–1058.

[54] M. D. Luecken, M. Büttner, K. Chaichoompu, et al., “Benchmarking Atlas-Level Data Integration in Single-Cell Genomics,” Nature Methods 19, no. 1 (2022): 41–50.

[55] M. A. Skinnider, J. W. Squair, C. Kathe, et al., “Cell Type Prioritization in Single-Cell Data,” Nature Biotechnology 39, no. 1 (2021): 30–34.

[56] P. B. Nicol, D. Paulson, G. Qian, X. S. Liu, R. Irizarry, and A. D. Sahu, “Robust Identification of Perturbed Cell Types in Single-Cell RNA-Seq Data,” Nature Communications 15, no. 1 (2024): 7610.

[57] X. Yi, J. Li, X. Zheng, et al., “Construction of PANoptosis Signature: Novel Target Discovery for Prostate Cancer Immunotherapy,” Molecular Therapy—Nucleic Acids 33 (2023): 376–390.

[58] M. D. Robinson, D. J. McCarthy, and G. K. Smyth, “edgeR: A Bioconductor Package for Differential Expression Analysis of Digital Gene Expression Data,” Bioinformatics (Oxford, England) 26, no. 1 (2010): 139–140.

[59] Y. Zhou, B. Zhou, L. Pache, et al., “Metascape Provides a Biologist-Oriented Resource for the Analysis of Systems-Level Datasets,” Nature Communications 10, no. 1 (2019): 1523.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.